About Event

The Only Industry-Focused Gene Editing Meeting

By spotlighting the emerging cutting-edge technologies, whilst also battling the key challenges limiting preclinical and clinical success, the 6th Genome Editing Therapeutics Summit sought to provide you and your team with the insights needed to maximize the potential for your therapies.  

Attendees collaborated with senior experts working across discovery, R&D, delivery, preclinical and clinical development, to streamline their end-to-end development. They also heard the latest data, from novel technologies and innovative platforms through to the leading clinical programs, to support their building of robust strategies to break new therapeutic ground.  

What You Missed

Leveraging learnings from leading assets to support your team in building unbreakable clinical strategies with Bluebird Bio

Identifying innovative technology platforms to improve editing accessibility and  therapeutic safety with nChromaBio and Metagenomi

Evaluating the benefits of viral and non-viral approaches to mediate precise targeting with Mammoth Biosciences and nChromaBio

Enhancing translatability and boost scalability through biomarker discovery with Modalis Therapeutics and Apellis Pharmaceuticals

Discussing approaches to accelerate progression from discovery through to commercialization with Prime Medicine and Novartis

Connect with Leading Experts

6th Genome Editing Therapeutics Summit - Companies in the Room 3

“I am excited to be a part of this summit, which brings together leading voices in this rapidly evolving field. This meeting provides a timely platform to explore how we can innovate and translate these tools into safe and effective therapies for patients”

Anna Gough, Scientist, Tune Therapeutics, 2025 Speaker 

2025 Program
Register Interest
Partner